Belén Garijo, Merck KGaA CEO (Arne Dedert/picture alliance via Getty Images)
June 24, 2024 03:41 PM EDT
R&D

Mer­ck KGaA's bet on head and neck can­cer drug from De­bio­pharm ends in Phase 3 fail­ure

Drew Armstrong

Executive Editor

Mer­ck KGaA’s Phase 3 tri­als of xev­ina­pant, the can­cer drug it li­censed from De­bio­pharm in 2021, are wind­ing down af­ter the drug showed that it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Im­munol­o­gy biotech Alu­mis se­cures $250M in shrunk­en IPO

Au­toim­mune brain dis­ease start­up Ar­ialys gets new leader; In­tel­lia, Arv­inas ap­point CFOs

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

To tack­le a dead­ly brain dis­ease, sci­en­tists de­vise small but charm­ing epi­ge­net­ic edit­ing tool

Supreme Court nar­row­ly re­jects Pur­due bank­rupt­cy plan, says it gives Sack­lers too much pro­tec­tion

What Co­herus' $40M sale of its Hu­mi­ra biosim­i­lar says about the crowd­ed mar­ket

A service from the Financial Times